Aplagon

Aplagon is a clinical-stage biopharmaceutical company pioneering the development of innovative, first-in-class therapies for thrombo-inflammatory diseases. The company focuses on developing APAC, a first-in-class heparin proteoglycan mimetic for thrombo-inflammatory diseases. APAC combines antiplatelet, anticoagulant and anti-inflammatory effects while selectively targeting vascular injury sites, providing long-acting local activity with limited systemic exposure.

Aplagon's programs target critical unmet medical needs to improve outcomes in these challenging thrombo-inflammation conditions such as Arteriovenous Fistula (AVF) maturation failure for hemodialysis and Critical Limb Ischemia (CLI), both of which have limited or no effective therapies. Lead indications are AVF maturation failure in haemodialysis patients and PAOD/CLTI to prevent amputations and major cardiovascular events.